SuperworthVeradermics EPS MANE
Diluted earnings per share by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$0.58
Veradermics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$0.58.
Earnings per share over time
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier |
|---|---|---|---|
| Q2 FY26 | −$0.58 | n/a | |
| Q1 FY26 | −$1.32 | n/a | |
| Q2 FY25 | −$24.19 | n/a | |
| Q1 FY25 | −$19.79 | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Veradermics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MANEVeradermics | n/m | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| ARQTArcutis Biotherapeutics | $0.22 | |
| LQDALiquidia | $1.39 | |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| Peer median | $1.00 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Veradermics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.